Regeneron Pharmaceuticals (REGN) short interest is $865 million; 2.01 million shares shorted; 2.53% of float; stock borrow is 30 bp fee (general collateral). REGN is the 10th most shorted stock in the U.S. Biotech sector.
REGN is down -1.5% today, -$6.51/share, along with most of the pharma and biotech names on continued fears of the possibility of negative pricing impact from UK and US regulatory bodies. Both UK and US lawmakers, including Senator Bernie Sanders, are challenging pricing decisions of several popular drugs.
We are seeing increased short selling today which continues the surge of short selling since mid-January. Shares shorted are up almost 200k shares, +11%, in just over two weeks. Other Biotech stock that have had increased short selling over the last month are Celgene Corp (CELG), Sarepta Therapeutics (SRPT) and Sage Therapeutics (SAGE).
Want deeper insight into the above analysis?
Contact:Â [email protected]
Managing Director Predictive Analytics, S3 Partners, LLC
For more information on S3â€™s reporting, data and analytics solutions, email us at [email protected]. Start your free trial of the BLACK App â€“ the only source of real-time short interest on the Bloomberg Terminal or Thomson Reuters Eikon.
For short side data and access to our research reports go to https://shortsight.com/.
The information herein (some of which has been obtained from third party sources without verification) is believed by S3 Partners, LLC (â€śS3 Partnersâ€ť) to be reliable and accurate.Â Neither S3 Partners nor any of its affiliates makes any representation as to the accuracy or completeness of the information herein or accepts liability arising from its use.Â Prior to making any decisions based on the information herein, you should determine, without reliance upon S3 Partners, the economic risks and merits, as well as the legal, tax, accounting and investment consequences, of such decisions.